

## NON-PREFERRED PPI PRODUCTS

### GPI CODING:

|                |                                    |
|----------------|------------------------------------|
| 492700761006** | Aciphex                            |
| 492700251030** | Nexium Granules                    |
| 492700251065** | Nexium Capsules                    |
| 492700400072** | Lansoprazole solutabs/ODT          |
| 492700701030** | Protonix Pak                       |
| 499960026030** | Zegerid powder                     |
| 49996002600**  | Omeprazole sodium bicarbonate Caps |

### DESCRIPTION:

Brand name proton pump inhibitors have a variety of FDA approved indications, however they are typically used for the treatment of GERD, erosive esophagitis, and hypersecretory conditions such as Zollinger-Ellison Syndrome. The purpose of this document is to provide approval criteria and guidelines for medical exceptions for brand name proton pump inhibitors prior to being a covered benefit. Claims submitted without obtaining prior authorization of benefits will reject on the pharmacy claim system.

### APPROVAL DURATION:

Approval duration: lifetime

### CRITERIA FOR NON-PREFERRED PPIS

For patients older than 18 years of age:

- I. Patient has demonstrated a trial of or documented serious adverse event to a 30 day supply of generic omeprazole 40mg/day **AND**
  - II. Patient has demonstrated a trial of or documented serious adverse event to a 30 day supply of Dexilant 60mg per day **AND**
  - III. Patient has demonstrated a trial of or documented serious adverse event to a 30 day supply of lansoprazole 30mg/day **AND**
  - IV. Patient has demonstrated a trial of or documented serious adverse event to a 30 day supply of pantoprazole 40mg/day
- AND ONE OF THE FOLLOWING**
- V. If Prevacid Solutab or lansoprazole ODT is being requested, the patient must have difficulty swallowing (no pantoprazole trial required)
  - VI. If AcipHex, Nexium or Protonix 40 mg Delayed-Release Granules for Suspension is being requested, the patient must have demonstrated a trial of or documented serious adverse event to a 30 day supply each of a total daily dose of pantoprazole 40 mg per day **AND** lansoprazole 30 mg per day
  - VII. If Zegerid Powder for Suspension or sodium-bicarbonate 40/1100 mg capsules is being requested, the patient must have demonstrated a trial of or documented serious adverse event to a 30 day supply each of a total daily dose of pantoprazole 40 mg per day, lansoprazole 30 mg per day **AND** Zegerid OTC

## NON-PREFERRED PPI PRODUCTS

For patients less than 18 years of age:

- I. Patient has demonstrated a trial of or documented serious adverse event to a 30 day supply of omeprazole 40mg/day **AND**
- II. Patient has demonstrated a trial of or documented serious adverse event to a 30 day supply of lansoprazole 30 mg/day

**AND ONE OF THE FOLLOWING**

- III. If Prevacid Solutab or lansoprazole ODT is being requested, the patient must have difficulty swallowing (exception: for ages 5 and under, lansoprazole ODT will be covered automatically)
- IV. If AcipHex, Nexium or Protonix 40 mg Delayed-Release Granules for Suspension is being requested, the patient must have demonstrated a trial of or documented serious adverse event to a 30 day supply each of a total daily dose of pantoprazole 40 mg
- V. If Zegerid Powder for Suspension or omeprazole-sodium bicarbonate 40/1100 mg capsules is being requested, the patient must have demonstrated an inadequate treatment response to or documented serious adverse event to a 30 day supply each of a total daily dose of pantoprazole 40 mg **AND** Zegerid OTC